Estrigenix Therapeutics one of five Wisconsin companies awarded SBIR Advance Phase 1 funding from WEDC

Estrigenix Therapeutics was one of five Wisconsin-based companies awarded matching funding from the SBIR Advance Phase 1 program funded by the Wisconsin Economic Development Corporation.

The SBIR Advance program provides assistance to companies in the process of completing a project in the federal Small Business Innovation Research (SBIR) program. feedback and reviewed multiple proposals from Estrigenix before giving Estrigenix the green light for the SBIR Ready funding.

Over a nine year period, 157 awards totaling nearly $13 million have been awarded. Those businesses reported obtaining $64 million in follow on funding since receiving the SBIR Advance matching grants.

Read the full article here.